Study to Evaluate the Efficacy Safety and Tolerability of Ultevursen in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene (Sirius)

Summary

The purpose of this study is to evaluate the efficacy safety and tolerability of ultevursen administered via intravitreal injection (IVT) in subjects with Retinitis Pigmentosa (RP) due to mutations in exon 13 of the USH2A gene.

Timeline

Start

2021-12-08

Primary completion

2022-10-12

Completion

2022-10-12

Outcome

Outcome not reported

Stopped (Business): “Business decision”

Drugs

Indications